Chất lượng cuộc sống 2

Schieber GJ, Poullier JP. Overview of international comparisons of health care expenditures. In: Health Care Financing Review. 1989 Annual Supplement. [HCFA Pub. No. 03291. Office of Research and Demonstrations, Health Care Financing Administration.] Washington: U.S. Government Printing Office, 1989:1–7. McPherson K. International differences in medical care practices. In: Health Care Financing Review. 1989 Annual Supplement. [HCFA Pub. No. 03291. Office of Research and Demonstrations, Health Care Financing Administration.] Washington: U.S. Government Printing Office, 1989:9–20. PMA Newsletter 1989;31(28):July 24. Levitt KR, Lazenby HC, Cowan CA, Letsch SW. National health expenditures, 1990. In: Health Care Financing Review. Vol. 13. [HCFA Pub. No. 03321. Office of Research and Demonstrations, Health Care Financing Administration.] Washington: U.S. Government Printing Office, 1991:29–54. Sonnefeld ST, Waldo DR, Lemieux JA, McKusick DR. Projections of national health expenditures through the year 2000. In: Health Care Financing Review. Vol. 13. [HCFA Pub. No. 03321. Office of Research and Demonstrations, Health Care Financing Administration.] Washington: U.S. Government Printing Office, 1991:1–27. Manasse HR. Medication use in an imperfect world: drug misadventuring as an issue of public policy. Am J Hosp Pharm 1988;46:929–42. Hartzema AG, ed. Pharmaceutical chartbook. Chelsea: Lewis, 1990:13–255. Freidman RB, Katt JA. Cost-benefit issues in the practice of internal medicine. Arch Intern Med 1991;151:1165–8. Bootman JL, Townsend RJ, McGhan WF. Introduction to pharmacoeconomics. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics. Cincinnati: Harvey Whitney, 1991:3–17. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. New York: Oxford University Press, 1987. Osterhaus JT, Draugalis JR. Application of pharmacoeconomics for drug therapy decisions. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmacoeconomics. Cincinnati: Harvey Whitney, 1991:134–45. Draugalis JR, Bootman JL, Larson LN, McGhan WF. Pharmacoeconomics: current concepts. Kalamazoo: Upjohn Company, 1989. Drummond M, Smith GT, Wells N. Economic evaluation in the development of medicines. London: Office of Health Economics, 1988. Dao TD. Cost-benefit and cost-effectiveness analysis of drug therapy. Am J Hosp Pharm 1985;42:791–802. Ganz PA. Methods of assessing the effect of drug therapy on quality of life. Drug Safety 1990;5(4):233–42. Pathak DS, Reardon G. Health status and pharmaceutical programmes: from cost minimization to cost-utility analysis. Top Hosp Pharm Manage 1988;8(3):66–77. Dao TD. Cost-effectiveness of drug therapy: the basic ingredients. Hospital Ther 1990;15:39–45. Weinstein MC, Stason WB. Foundation of cost-effectiveness analysis for health and medical practice. N Engl J Med 1977;296:716–21. Larson LN. Cost determination and analysis. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of pharmaco-economics. Cincinnati: Harvey Whitney, 1991:134–45. Patrick KM, Woolley FR. A cost-benefit analysis of immunization for pneumococcal pneumonia. JAMA 1981;245:473–7. Einarson TR, McGhan WF, Bootman JL. Decision analysis applied to pharmacy practice. Am J Hosp Pharm 1985;42:364–71. Kassirer JP, Moskowitz AJ, Lau J, Pauker SG. Decision analysis: a progress report. Ann Intern Med 1987;106:257–91. Willems JS. Cost-effectiveness and cost-benefit analyses of vaccines. J Infect Dis 1981;144:486–93. Edelson JT, Tosteson ANA, Sax P. Cost-effectiveness of misoprostol for prophylaxis against nonsteroidal anti-inflammatory drug-induced gastrointestinal tract bleeding. JAMA 1990;264:41–7. Chin A, Gill MA, Ito MK, Yellin AE, Berne TV, Heseltine PNR, Appleman MD. Cost-analysis of two clindamycin dosing regimens. Drug Intell Clin Pharm 1989;23:980–3. Kaplan RM, Anderson JP. The general health policy model: an integrated approach. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, 1990:131–49. Bergner M. Quality of life, health status, and clinical research. Med Care 1989;27(3):S148–56. Patterson M. Assessment of treatment in rheumatoid arthritis. In: Smith GT, ed. Measuring health: a practical approach. New York: John Wiley & Sons, 1988:157–90. Torrance GW. Utility approach to measuring health-related quality of life. J Chron Dis 1987;40(6):593–600. Feeny D, LaBelle R, Torrance GW. Integrating economic evaluation and quality of life assessments. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, 1990:71–83. Guyatt GH, Jaeschke R. Measurements in clinical trials: choosing the appropriate approach. In: Spilker B, ed. Quality of life assessments in clinical trials. New York: Raven Press, 1990:37–46. Patrick DL, Deyo RA. Generic and disease-specific measures in assessing health status and quality of life. Med Care 1989;27(3):S217–32. Schipper H, Clinch J. Assessment of treatment in cancer. In: Smith GT, ed. Measuring health: a practical approach. New York: John Wiley & Sons, 1988:109–56. Patterson M. Assessment of treatment in rheumatoid arthritis. In: Smith GT, ed. Measuring health: a practical approach. New York: John Wiley & Sons, 1988:157–90. Goodwin PJ, Feld R, Evans WK, Pater J. Cost-effectiveness of cancer chemotherapy: an economic evaluation of a randomized trial in small-cell lung cancer. J Clin Oncol 1988;6:1537–47. Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient? Br J Cancer 1988;57:109–12. Drummond MF, Stoddart GL. Economic analysis and clinical trials. Control Clin Trials 1984;5:115–28. Dao TD. Cost-effectiveness of drug therapy: the current status. Hospital Ther 1990;15:339–48. Gagnon JP, Osterhaus JT. Proposed drug-drug cost effectiveness methodology. Drug Intell Clin Pharm 1987;21:211–6.